In search of novel therapies, the team examined multiple DIPG cultures with “combination” studies, including testing thousands of approved and investigational drug pairs. In recent years, studies have shown that diffuse intrinsic pontine glioma (DIPG) subtypes are driven by common genetic mutations, particularly in genes encoding histones, which are associated with epigenetic modifications.
